Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
68.37
-2.44 (-3.45%)
At close: Jun 27, 2025, 4:00 PM
67.42
-0.95 (-1.39%)
After-hours: Jun 27, 2025, 6:19 PM EDT
Incyte Revenue
Incyte had revenue of $1.05B in the quarter ending March 31, 2025, with 19.53% growth. This brings the company's revenue in the last twelve months to $4.41B, up 17.13% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.41B
Revenue Growth
+17.13%
P/S Ratio
3.08
Revenue / Employee
$1,686,368
Employees
2,617
Market Cap
13.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INCY News
- 2 days ago - Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire - Business Wire
- 7 days ago - Incyte Says FDA Extended Review Period for Opzelura - Market Watch
- 9 days ago - Incyte Lymphoma Treatment Gets FDA Approval - Market Watch
- 9 days ago - Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma - Business Wire
- 13 days ago - QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Business Wire
- 13 days ago - Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 - Business Wire
- 15 days ago - Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - Business Wire
- 21 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire